Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
- Conditions
- Parkinson Disease
- Interventions
- Diagnostic Test: Clinical assessmentDiagnostic Test: Pain characteristics assessmentDiagnostic Test: MRIDiagnostic Test: ThermotestDiagnostic Test: UPDRS-III ScaleDiagnostic Test: [18F]-MPPF PET scan
- Registration Number
- NCT06008704
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
This project will explore the involvement of the serotonin system in the pathophysiology of PD-related central pain. Thus, the serotonin system will be evaluated in PD patients with and without central pain who will benefit from brain positron emission tomography (PET) allowing in vivo imaging of 5HT1A receptors and multimodal brain MRI including morphometric imaging and functional connectivity (resting state acquisition).
- Detailed Description
The prevalence of chronic pain in PD can be estimated at 60-80% from several epidemiological studies. Both semiological and pathophysiological classification proposes specific and non-specific pain in PD. While non-specific pain is not directly related to PD but may be aggravated by the disease, specific pain is a direct result of the disease with dystonic pain characterized by painful cramps in relation to motor symptoms and non-systematic central pain such as burning, paresthesia, compression (central parkinsonian pain). A case-control study reported that cramp-like pain and central pain were three times more frequent in parkinsonian patients than in the general population. Pathophysiologically, several studies suggest an abnormal nociceptive integration process in PD patients. Previous studies have indicated that the nociceptive signal is amplified along the pain transmission pathways. This could be related to increased facilitation through central sensitization of pain pathways or decreased inhibition (reduced activity of descending inhibitory control systems). Several recent studies suggest that the noradrenergic and/or serotonergic systems may be involved in the pathophysiology of PD-related pain. Therefore, this project will explore the involvement of the serotonergic system in the pathophysiology of pain using brain neuroimaging in PD patients with central pain.
The present study hypothesize that the binding of the radiotracer \[18F\]-MPPF, allowing in vivo imaging of 5HT1A receptors, will be reduced in PD patients with central pain compared to non-painful PD patients at the level of the median raphe, but also at the level of several brain structures involved in the pain matrix such as the insula, the anterior and posterior cingulate cortex, the orbitofrontal cortex, etc. A correlation between the clinical parameters of pain and the brain structures in which MRP binding is decreased should make it possible to confirm the link between these serotonin binding anomalies and pain. Finally, the morphological and functional MRI study should make it possible to identify structural and functional abnormalities within the pain networks in painful Parkinson's patients.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 34
-
Patients with PD defined according to United Kingdom Parkinson's Disease Brain Bank (UKPDSBB) criteria
-
Patients with stable anti-parkinsonian treatment for at least 4 weeks prior to inclusion
-
Patients with a Montreal Cognitive Assessment (MoCA) score > 25
-
Patients with a Hospital Anxiety and Depression Scale (HADS)-D score ≥ 11
-
Person affiliated or benefiting from a social security scheme.
-
Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
• For patients with pain
-
Patients with PD-related central pain defined according to the criteria of Marques et al, 2019
-
Patients with chronic central pain (i.e. present for at least 3 months)
-
Patients who have average pain over the previous month according to a VAS ≥ 4.
• For patients without pain
-
Patients who do not have pain defined as VAS ≤ 4, meaning that it does not interfere with daily activity.
- Patients treated with second line therapy
- Patients with a history of significant psychiatric pathology according to the investigator
- Patients treated with drugs interacting with 5HT1A receptors in the previous 4 weeks
- Patients with contraindication to MRI
- Patients refusing to be informed of an abnormality discovered during brain imaging
- Patients with dyskinesias judged by the investigator to be disabling for imaging.
- Patients under guardianship or other legal protection, deprived of their liberty by judicial or administrative decision
- Pregnant woman, breastfeeding woman
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description PD patients with central chronic pain UPDRS-III Scale Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included PD patients without pain Pain characteristics assessment Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included PD patients without pain MRI Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included PD patients without pain Thermotest Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included PD patients with central chronic pain [18F]-MPPF PET scan Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included PD patients with central chronic pain Thermotest Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included PD patients without pain [18F]-MPPF PET scan Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included PD patients with central chronic pain Clinical assessment Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included PD patients with central chronic pain Pain characteristics assessment Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included PD patients with central chronic pain MRI Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients presenting central chronic pain will be included PD patients without pain Clinical assessment Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included PD patients without pain UPDRS-III Scale Patients from both groups will receive the same interventions, the difference between groups is the eligibility criteria. In this arm only patients without central chronic pain will be included
- Primary Outcome Measures
Name Time Method Distribution volume ratio of [18F]-MPPF during the procedure The MRP \[18F\]-MPPF marking the 5 HT1A receptors allows the in vivo visualization of serotonergic neurons and it's sensitive to extracellular variations of serotonin
- Secondary Outcome Measures
Name Time Method Pain perception thresholds and [18F]-MPPF uptake during the procedure Correlation between \[18F\]-MPPF uptake and pain perception thresholds, measured with the thermotest
Pain intensity and [18F]-MPPF uptake during the procedure Correlation between \[18F\]-MPPF uptake and central pain intensity measured with the Visual Analog Score for pain (Scale from 0 to 10, 10 being the most fote intensity of pain)
Functional impairment and [18F]-MPPF uptake during the procedure Correlation between \[18F\]-MPPF uptake and functional impairment, measured with the Primary Parkinsonian Pain Diagnostic Questionnaire .
It is a 39-item self-questionnaire evaluating the motor and psychological quality of life of Parkinson's patients over the past month. Each question is rated from 0 (no disturbance) to 4 (maximum disturbance), and items are divided into 8 dimensions (mobility, activities of daily life, emotional well-being, psychological discomfort, social support, cognitive disorders, communication, physical discomfort).
A score is calculte in percentage. The higher the score, the lower the quality of life in this dimension. It is a simple and fast scale of transfer, reliable and validated, sensitive to change.Macrostructural markers during the procedure Measurement of macrostructural markers obtained by MRI Macrostructural markers measured by T1 and T2 sequences: density of gray matter
Central pain characteristics measured by Visual Analog Score for pain (VAS) and brain macrostructural markers during the procedure Correlation between brain macrostructural markers and central pain characteristics measured with the Visual Analog Score for pain (VAS) which consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be')
Behavioral population characteristics obtained with the Hospital Anxiety and Depression scale (HAD) during the procedure Mean of patient's behavioral characteristics score obtained with the Hospital Anxiety and Depression scale (HAD) which is scored between 0 meaning no impairment and 3 being severe impairment
5HT1A-receptors specific radioligand binding and functional networks connectivity during the procedure Correlation between 5HT1A receptors specific radioligand binding and functional networks connectivity, obtained by IRM
Motor population characteristics obtained with the Movement Disorders Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) during the procedure Mean of patient's motor characteristics score obtained with the Movement Disorders Society-sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS), which score ranges from 0 to 260, with 0 indicating no disability and 260 indicating total disability
Trial Locations
- Locations (1)
Centre Hospitalier Universitaire de Toulouse
🇫🇷Toulouse, Haute-Garonne, France